According to the Zhitong Finance App, Superstar Medical Holdings (02393) announced its annual results for the year ended December 31, 2023. The group achieved continuous business revenue of 2,913 billion yuan (RMB, same below) during the period, an increase of 3.86% over the previous year; losses attributable to shareholders were 13.888 million yuan, a year-on-year decrease of 98.6%; and a basic loss of 0.6 points per share.
According to the announcement, demand for the Group's in vitro diagnostic consumables increased in 2023, mainly due to a sharp rise in demand for cardiomyocardial products from patients with diseases caused by COVID-19 in the first quarter of 2023. Revenue from continuing operations in this segment reached $2,676 billion (2022: $2,541 million), an increase of 5.3% year-on-year. The segment's gross profit from continuing operations was $470 million (2022: $395 million). The gross margin of continuing operations in this segment also increased 2.1 percentage points to about 17.6% (2022:15.5%), mainly due to the increase in sales share of high-margin cardiomyocardial products.